TheStreet Reiterates “Hold” Rating for Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by analysts at TheStreet in a research report issued to clients and investors on Monday, AnalystRatingsNetwork.com reports.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company’s earnings per share.”
In other Regeneron Pharmaceuticals news, major shareholder Sanofi purchased 157,920 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was purchased at an average price of $275.90 per share, for a total transaction of $43,570,128.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Several other analysts have also recently commented on the stock. Analysts at BMO Capital Markets downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, January 15th. They now have a $331.00 price target on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Friday, January 10th. They now have a $340.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $323.00 to $344.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $305.66.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 291.1701 on Monday. Regeneron Pharmaceuticals has a 52-week low of $154.16 and a 52-week high of $319.83. The stock’s 50-day moving average is $278.8 and its 200-day moving average is $278.7. The company has a market cap of $28.600 billion and a price-to-earnings ratio of 41.09.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.